Proteomics International Laboratories Ltd Stock Market Press Releases and Company Profile

Held at the 19th ISDE World Congress for Esophageal Diseases in Toronto, Canada, held 8-10 September 2023

New Oesophageal Cancer Test Presented at Global Conference
New Oesophageal Cancer Test Presented at Global Conference

Perth, Sep 8, 2023 AEST (ABN Newswire) - Proteomics International Laboratories Ltd (googlechartASX:PIQ) is pleased to announce its latest results for its novel blood test for oesophageal adenocarcinoma will be presented tomorrow at the 19th ISDE World Congress for Esophageal Diseases in Toronto, Canada, held 8-10 September 2023.

- Proteomics International's new PromarkerEso blood test shows strong discrimination of oesophageal cancer

- Test targets both oesophageal adenocarcinoma and patients with pre-malignant condition Barrett's oesophagus which affects 1-2% of adults and can arise from chronic acid reflux

- Advanced discrimination system correctly identified 89% of patients with oesophageal adenocarcinoma and 92% of patients without the disease

- Latest results presented tomorrow at the 19th ISDE World Congress for Esophageal Diseases in Toronto, Canada

- Oesophageal cancer is the 6th leading cause of cancer-related mortality, the 7th most common cancer globally and has a 20% five-year survival rate

- Current screening requires a specialist endoscopy procedure and the annual expenditure on treating oesophageal cancer in the US is $2.9 billion

The conference presentation builds upon earlier work which identified and validated a panel of glycoprotein biomarkers using 300 samples from two independent clinical cohorts [ASX 27 September 2022].

Oesophageal adenocarcinoma is the most common form of oesophageal cancer with a five-year survival rate of approximately 20%. Oesophageal cancer and its pre-malignant condition Barrett's oesophagus can develop from chronic acid reflux. One in twenty cancer deaths worldwide in 2018 were attributed to oesophageal cancer.

Proteomics International Managing Director Dr Richard Lipscombe said the prototype test, named PromarkerEso, was now showing strong discrimination at early and late stages of the disease. "We've refined our diagnostic models to correctly identify 89% of patients with oesophageal adenocarcinoma and 92% of patients without the disease. This means we could have a simple blood test to determine who would benefit from an endoscopy. We believe that such a test would garner significant clinical and commercial interest should it be further validated."

Screening for oesophageal adenocarcinoma currently requires a specialist endoscopy procedure that costs US$2,750 per patient in the United States , where the total expenditure on treating oesophageal cancer was $2.9 billion in 2018. This cancer represents an area of significant unmet medical need, and the Company believes there is large market potential for a simple diagnostic test.

The new results apply Proteomics International's 'traffic light' scoring system to categorise patients as green (low risk), amber (moderate risk) or red (high risk) for oesophageal adenocarcinoma. The results also suggest some individuals may have been misdiagnosed, although further work is required to confirm this.

Proteomics International's test uses biomarkers-protein 'fingerprints' in the blood-to diagnose both oesophageal adenocarcinoma and Barrett's oesophagus. An estimated 10-15% of patients with chronic acid reflux develop Barrett's oesophagus, a condition which is asymptomatic and affects 1-2% of Western populations . People with Barrett's oesophagus are much more likely to get oesophageal adenocarcinoma, and are advised to get regular endoscopies to screen for oesophageal cancer [PIQ Annual Report 2022].

Engaging with Key Opinion Leaders (KOLs) who could guide early adoption of PromarkerEso is an important objective for the Company in attending the conference. These potential relationships would build upon Proteomics International's recent agreement to access 350 additional patient samples from the Victorian Cancer Biobank [ASX 23 July 2023]. The cohort comprises blood samples from oesophageal and other selected cancer patients. These samples will be used for external validation of the accuracy of the Company's current prototype oesophageal cancer test, with results expected early next year.

Dr Lipscombe said the next steps in commercialising the PromarkerEso test are to:

- streamline the biomarker measurements to produce a test suitable for the US Laboratory Developed Test (LDT) pathway via CLIA certified clinical laboratories;

- confirm the clinical performance of the test in an additional independent patient cohort; and

- conduct formal Economic Health Benefit Modelling and Clinical Utility Studies to demonstrate how the new test could significantly change doctors' treatment decisions and improve outcomes for patients and healthcare systems.

The Company anticipates that these steps will be completed over the next 9 months.

To view the International Society for Diseases of the Esophagus 19th World Congress 2023, Oral presentation, please visit:

Summary of the Diagnostic Test Development and Validation Study

Method: To generate the diagnostic test Proteomics International's scientists analysed clinical samples from a development cohort of 249 people collected by the Progression of Barrett's Esophagus to Cancer Network (PROBENET, Australia). Patients were classified as having esophageal adenocarcinoma [EAC]; positive for Barrett's esophagus [BE+] and BE with low grade dysplasia; Barrett's esophagus with high grade dysplasia (severely abnormal cells) [BEHGD]; negative controls. A series of statistical models were then built using protein biomarkers to attain optimal diagnostic performance in the development cohort. The performance of the statistical models was then tested in an independent validation cohort of 49 patient samples from the Ochsner Health System in New Orleans, United States.


Robust assay method for measuring the glycoprotein biomarkers developed (intraday CV = 9.3%; interday CV = 11.5%) suitable for use as a Laboratory Developed Test (LDT) via a specialist CLIA (US) certified clinical laboratory.

Panel of glycoprotein biomarkers confirmed that showed significant correlation with disease progression.

Diagnostic model for discriminating disease severity performed strongly in the validation cohort:

- For negative controls vs EAC: Area Under the Curve (AUC) 0.94, Sensitivity (Sn) 80%, Specificity (Sp) 93%.

- For negative controls vs EAC and BE-HGD: AUC 0.79, Sn 59%, Sp 93%.

Comment: these tests offer the potential to provide an early screening tool to minimise the requirements for an endoscopy.

For comparison, the statistical performance of the Prostate-Specific Antigen (PSA) diagnostic test (blood test measuring the concentration of the PSA protein) for the diagnosis of prostate cancer is:

- Prostate cancer versus no cancer: AUC 0.68

- PSA cut-off threshold 3ng/ml: Sensitivity 32%, Specificity 87%

Conclusions: A diagnostic test has been developed using novel serum glycoprotein biomarkers to provide a potential screening tool for both esophageal adenocarcinoma and Barrett's esophagus with high grade dysplasia.

In interpreting these results it is important to recognise that the total cohort size is 300 patients and the validation cohort is relatively small. Consequently, further work in additional patient samples is required to confirm the clinical accuracy of the PromarkerEso test.

Proteomics International is currently rolling-out PromarkerD, a simple blood test for predicting diabetic kidney disease. The Company also has advanced research programs targeting novel diagnostics for endometriosis, oxidative stress, asthma and COPD.

About the PromarkerTM Platform

Proteomics International's diagnostics development is made possible by the Company's proprietary biomarker discovery platform called Promarker, which searches for protein 'fingerprints' in a sample. This disruptive technology can identify proteins that distinguish between people who have a disease and people who do not, using only a simple blood test. It is a powerful alternative to genetic testing. The technology is so versatile it can be used to identify fingerprints from any biological source, from wheat seeds to human serum. The Promarker platform was previously used to develop PromarkerD, a world-first predictive test for diabetic kidney disease, that is currently being commercialised. Other tests in development include for asthma & COPD, oesophageal cancer, diabetic retinopathy and oxidative stress.

About Proteomics International Laboratories Ltd

Proteomics International Laboratories LtdProteomics International Laboratories (ASX:PIQ) is a wholly owned subsidiary and trading name of PILL, a medical technology company at the forefront of predictive diagnostics and bioanalytical services. The Company specialises in the area of proteomics - the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease. 


Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992

Dirk van Dissel
Investor Relations & Corporate Advisor
Candour Advisory
T: +61 408 326 367

Kyle Moss
Corporate Advisor
Euroz Hartleys
T: +61 8 9488 1400

ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 17) (Last 30 Days: 145) (Since Published: 1620)